🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
KLR
$KLRS
🔒 US EquitiesKalaris Therapeutics Inc
AVG HISTORICAL GAP
-0.60%
MAX GAP RECORD
-2.71%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $KLRS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$KLRS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 18, 2026 Earnings Release 2026-11-18 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE) |
+2.52%
|
| May 12, 2026 Earnings Release 2026-05-12 (AFTER CLOSE) |
-2.71%
|
| Mar 17, 2026 Earnings Release 2026-03-17 (UNDETERMINED) |
+0.00%
|
| Nov 12, 2025 Earnings Release 2025-11-12 (UNDETERMINED) |
+0.00%
|
| Aug 13, 2025 Earnings Release 2025-08-13 (BEFORE OPEN) |
-1.61%
|
| May 14, 2025 Earnings Release 2025-05-14 (UNDETERMINED) |
+0.00%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.3%
Bullish Gaps (1)
Bearish Gaps (2)
Neutral / Flat (0)
📖 Intelligence Summary
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗